Pharmafile Logo

Genesis Research Group survey discovers how payers are responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act

December 6, 2024 |  

To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, Genesis Research Group employed their RPR stakeholder engagement platform and vetted stakeholder network to survey 12 payer organizations.

IRA payer survey results

How are payers responding to Maximum Fair Prices (MFPs) under the Inflation Reduction Act? Explore our findings.

To better understand how MFPs might impact payer utilization management strategies, rebate negotiations, and business approaches, we employed our RPR stakeholder engagement platform and vetted stakeholder network to survey 12 payer organizations. This included national and regional Managed Care Organizations (MCOs), Pharmacy Directors (PDs), Integrated Delivery Networks (IDNs), and Pharmacy Benefit Managers (PBMs), representing a total of 96 million MCO/IDN lives and 115 million PBM lives.

Our findings reveal critical insights into how payers are adapting to the recent release of MFPs for key pharmaceutical products under the IRA. For example:

💡 Payers view the MFPs for the diabetes and cardiovascular products most favorably and plan to leverage them in upcoming commercial rebate negotiations. However, payers see unmet needs for further discounts for the immunology and oncology products.

💡 Payers are divided on preferring MFP over non-MFP products due to the potential for non-MFP products to offer more aggressive rebates or better clinical benefits.

View the graphic above for further details.

This is just the first glimpse into a larger narrative. Follow us on LinkedIn to view Part Two of our findings and stay tuned for our interim report within the coming weeks. This report will offer further detail as to how MFPs could reshape both payer strategies and the healthcare market.

You can find out more about our RPR stakeholder engagement platform and global network of 3500+ vetted stakeholders online or contact solutions@genesisrg.com if you have questions or would like to request a copy of the report in advance.

Follow us on LinkedIn>>

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online

Genesis Research Group's poster 'Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey' was recently named as...

Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group

A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition...

Genesis Research Group unveils enhanced US market access data analytics

Genesis Research Group (“Genesis”), a pioneer of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the expansion of its real-world data analytics capabilities...

Assessing opportunities for manufacturers to communicate the value of therapies to oncology clinical pathway (OCP) developers

Based on insights from 15 U.S. payers and providers, this white paper explores how manufacturers can effectively engage oncology clinical pathway (OCP) developers.

Genesis Research Group Announces Participation of CEO David W. Miller in New ITN Business Healthcare Program

Genesis Research Group, led by newly appointed CEO, David W. Miller, is spotlighted in June’s launch of ITN Business’ “Advancing Healthcare” program for its ‘innovate differently’ approach to supporting life...

Alice Beer of ITN Business recently interviewed David W. Miller, CEO of Genesis Research Group, on ‘Advancing Healthcare’

ITN Business invited Genesis Research Group to contribute to a news style programme 'Advancing Healthcare' featuring key opinion leaders in the healthcare sector. Our CEO David W. Miller was one...

How does Genesis Research Group ‘Innovate differently’?

New Genesis Research Group CEO David W. Miller explains what we mean when we say we help our life science clients to 'Innovate differently' and transform the way they engage...

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group

A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com. With more and more innovative vaccines and immunization strategies...

Fit-for-purpose matchmaking webinar: a data selection and RWE approach for both regulatory and HTA audiences

This webinar reviews considerations for the design and data selection for RWE studies, including external control arm studies, to meet regulatory and HTA needs. Regulators and agencies responsible for market...